Chemours Co (CC) Q3 2025 10-Q Quarterly Report

Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Chemicals & Allied ProductsSEC EDGAR

Chemours Co (CC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Chemours Co Q3 2025 10-Q Analysis

Risk Factors

  • Newly added environmental compliance risk triggered by evolving U.S. and international laws including CERCLA, TSCA, EU REACH, and China MEE Order No. 12
  • Updated environmental remediation costs risk with accrual uncertainties due to site complexity, contamination extent, and PRP outcomes
+3 more insights

Chemours Co Q3 2025 Quarterly Financials
XBRL

Revenue

$1.5B

-0.4% YoY -7.4% QoQ

Net Income

$60M

+322.2% YoY +115.7% QoQ

Gross Margin

15.5%

-347bp YoY -170bp QoQ

Net Margin

4.0%

+581bp YoY +2760bp QoQ

ROE

20.1%

Total Assets

$7.6B

EPS (Diluted)

$0.40

+322.2% YoY +115.8% QoQ

Operating Cash Flow

$146M

+5.0% YoY +57.0% QoQ

Source: XBRL data from Chemours Co Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Chemours Co

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.